The Study discussed brief overview and in-depth assessment on Global High-flow Nasal Cannula Market 2018 including key market trends,upcoming technologies,industry drivers,challenges,regulatory policies,with key company profiles and overall competitive scenario.The market study can help them to make critical business decisions on production techniques,raw materials procurement,and to increase industry chain cycle of market across the globe.
Get Sample of Global High-flow Nasal Cannula Market 2018 Report @ http://www.orbisresearch.com/contacts/request-sample/2306081
The global High-flow Nasal Cannula market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.
The objectives of this study are to define, segment, and project the size of the High-flow Nasal Cannula market based on company, product type, end user and key regions.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Fisher & Paykel Healthcare Limited
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the High Flow Nasal Cannula market include Great Group Medical Co., Ltd., Salter Labs, TNI Medical Ag, Mek-Ics Co., Ltd., Flexicare Medical Limited.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global High Flow Nasal Cannula Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/high-flow-nasal-cannula-market/download-sampleMarket DynamicsRespiratory distress is one of the most common causes of hospitalization.
It has been increasingly used in a variety of clinical settings.
It overcomes flow limitations of low- and intermediate-flow devices by delivering up to 60 litres per minute of heated, humidified gas through nasal prongs.
The primary approach for COVID-19 patients is supportive care which includes oxygen therapy for hypoxemic patients, in which high-flow nasal cannula (HFNC) was reported as effective in improving oxygenation.